More Tantalizing Clues Oxytocin May Be an Effective Autism Treatment
In a preliminary presentation of new research, doctors said a nasal spray containing the hormone helped activate "social" regions of the brain.
Oxytocin, the "mother-infant bonding hormone," holds even more promise for helping treat the social deficits that are often part of autism spectrum disorder (ASD). Where earlier work piqued interest in oxytocin as a possible treatment, a new study goes further to support its role in treating the disorder, which now affects one in 88 children born today, according to the CDC.
The brains of the children who had received the oxytocin showed that areas of the "social brain," were activated.
MORE FROM THE DOCTOR WILL SEE YOU NOW
In the new study, the authors conducted a double-blind placebo-controlled trial, the gold standard of scientific research. The team gave half of a group of children aged 7-18 a single dose of a nasal spray containing oxytocin. The other half of the group received a placebo - a nasal spray with no active ingredient in it.
The brains of the children who had received the oxytocin showed that areas of the "social brain," were activated. These included the medial prefrontal cortex, the temporal parietal junction, the fusiform gyrus and the superior temporal sulcus, all areas involved in processing social information coming from sight, sounds, and cues from other people.
Oxytocin is secreted in large amounts during and after childbirth, and is thought to help a mother and her baby bond. It also appears to support other, non-maternal social behaviors, like feeling more open and trusting towards other people.
"Our findings provide the first, critical steps toward devising more effective treatments for the core social deficits in autism, which may involve a combination of clinical interventions with an administration of oxytocin," said study author Ilanit Gordon. "Such a treatment approach will fundamentally improve our understanding of autism and its treatment." The findings are preliminary, however, and the treatment will need more rigorous investigation before it could be recommended for use in the general public.
The study was carried out at Yale University, and the findings presented at the International Meeting for Autism Research in May. They are not yet scheduled to appear in a peer-reviewed journal.
This article originally appeared on TheDoctorWillSeeYouNow.com, an Atlantic partner site.